Truist Financial restated their buy rating on shares of Amneal Pharmaceuticals (NYSE:AMRX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the stock. Several other research firms also recently commented on AMRX. StockNews.com started coverage on Amneal Pharmaceuticals in a report on […]